Cannis Inc
MNIA
- -
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Technology
- Industry
- Software - Application
- Address
- United States of America
- Similar Companies
- Business
- Cannis Inc (NYSE American: MNIA) operates as a biotechnology company focused on developing innovative therapeutic solutions for unmet medical needs, primarily in the areas of oncology and rare diseases. The company offers a pipeline of clinical-stage product candidates, including small molecule inhibitors targeting cancer cell proliferation pathways; monoclonal antibodies for immune modulation in autoimmune disorders; and gene therapy platforms designed for genetic disease correction, with key programs such as MNIA-101, a next-generation CDK4/6 inhibitor in Phase II trials for advanced breast cancer, and MNIA-203, an AAV-based gene therapy for Duchenne muscular dystrophy. Cannis provides contract research organization services; biomarker discovery tools; and precision medicine diagnostics through its subsidiary Cannis BioLabs, serving pharmaceutical partners and academic institutions globally. Headquartered in San Diego, California, and founded in 2018, Cannis conducts operations across North America, Europe, and Asia-Pacific, with manufacturing facilities in the United States and clinical trial sites in over 15 countries targeting large pharma, biotech firms, and healthcare providers as primary customers. In the last 18 months, Cannis has undergone significant strategic developments, including a $75 million Series C funding round in March 2025 led by OrbiMed Advisors to accelerate MNIA-101's pivotal trials; the acquisition of Precision Genomics Ltd in July 2025 to expand its diagnostics portfolio and AI-driven drug discovery capabilities; a strategic alliance with AstraZeneca announced in October 2025 for co-development of oncology combination therapies; and the launch of MNIA-305, a bispecific T-cell engager for solid tumors, entering Phase I in November 2025. These initiatives reflect the company's shift toward integrated precision oncology platforms and expansion into AI-enhanced biomanufacturing.